Curatis Reports 30% Revenue Growth and Expands Patient Target for Lead Project

Curatis Holding AG has reported a revenue growth of 30% reaching CHF 6.9 million for 2024. Despite Curatis AG being included for only eight months, the year's revenue in the distribution business soared to CHF 9.5 million. Significant organic growth and new product introductions drove this increase.

Curatis plans to apply for a Biologics License for its lead project C-PTBE-01 in the U.S., potentially enhancing its market scope. Originally targeting pediatric Diffuse Midline Glioma (DMG) cases, the project now broadens to include more primary and metastatic brain tumors in both children and adults.

A meeting with the FDA to discuss a pivotal Phase-III study is scheduled for Q2 2025. Additionally, the company possesses a solid cash position of CHF 3 million, supporting its operations securely.